Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports the resolutions passed at the 150th Annual General Meeting of Shareholders held on June 24, 2026. The filing covers the conclusion of the 149th fiscal year, which ran from April 1, 2025, to March 31, 2026.
Key Financial Metrics
The filing confirms the reporting of Consolidated and Unconsolidated Financial Statements for the 149th fiscal year but does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within this document.
- Dividend: Approved a year-end dividend of 100 JPY per share.
- Director Bonuses: Approved a total bonus pool of up to 260 million JPY for two specific Directors (excluding those residing outside Japan and External Directors).
Material Changes
The filing does not contain comparative financial data or analysis of material changes versus the prior period. It focuses on corporate governance resolutions.
Guidance, Outlook, and Corporate Actions
Management commentary is limited to the notification of shareholder resolutions. Key corporate actions include:
- Board Elections: Re-election of six directors (Milano Furuta, Andrew Plump, Masami Iijima, Steven Gillis, John Maraganore, Miki Tsusaka) and new election of Julie Kim and Paul Stoffels to the Board of Directors (non-Audit and Supervisory Committee).
- Audit Committee Elections: Re-election of Kimberly A. Reed and new election of Bruce Broussard and Koichiro Kimura as Audit and Supervisory Committee Members.
- Substitute Director: Paul Stoffels was elected as a Substitute Director for the Audit and Supervisory Committee.
- External Directors: Masami Iijima, Steven Gillis, John Maraganore, Miki Tsusaka, Paul Stoffels, Kimberly A. Reed, Bruce Broussard, and Koichiro Kimura are classified as External Directors.
Investor Verification Checklist
- Verify the full Consolidated Financial Statements for the fiscal year ended March 31, 2026, in the company's Form 20-F or annual report to obtain specific revenue and profit figures.
- Confirm the exact payout date for the approved 100 JPY per share dividend.
- Review the specific criteria for the 260 million JPY director bonus allocation.
- Check for any subsequent filings regarding the new directors' compensation packages.